Journal Watch · Cell Metabolism · 2026

Large-scale metaproteomics of human gut microbiota reveals microbial functions in metabolic diseases and aging.

This study provides protein-level evidence of microbial functions in health and disease, highlighting potential therapeutic targets.

Liang S, Sun Y, Miao Z et al.Cell Metabolism3 min readPharma relevance 40/100

DOI: 10.1016/j.cmet.2026.02.012PMID: 41831436Study type: cohort / observational clinical study

TL;DR

This study provides protein-level evidence of microbial functions in health and disease, highlighting potential therapeutic targets.

Key findings

  • Experimental validation indicates that M. elsdenii is promoted by antidiabetic drugs and may regulate glucose homeostasis through butyrate production.
  • This study provides protein-level evidence of microbial functions in health and disease, highlighting potential therapeutic targets.

What they did

Across metabolic diseases, we observe the consistent depletion of Bacillota species and their proteins involved in carbohydrate, energy, amino acid metabolism, and short-chain fatty acid production. We also identify medication-associated features across diabetes, hypertension, and dyslipidemia. Validated in an independent cohort, Megasphaera elsdenii emerged as a hub species in type 2 diabetes.

Full abstract (original)

Background: The protein-level functionalities of the human gut microbiota in large populations, and their associations with host factors, remain unexplored. This study reports a metaproteomic study of 1,967 fecal samples from 1,399 middle-aged and elderly Chinese individuals, identifying microbial functions linked to 44 phenotypes. We uncover aging-associated functional shifts in carbon metabolism and energy production driven by species within the Bacillota, Bacteroidota, Actinomycetota, and Pseudomonadota.

What they did: Across metabolic diseases, we observe the consistent depletion of Bacillota species and their proteins involved in carbohydrate, energy, amino acid metabolism, and short-chain fatty acid production. We also identify medication-associated features across diabetes, hypertension, and dyslipidemia. Validated in an independent cohort, Megasphaera elsdenii emerged as a hub species in type 2 diabetes.

Results & conclusions: Experimental validation indicates that M. elsdenii is promoted by antidiabetic drugs and may regulate glucose homeostasis through butyrate production. This study provides protein-level evidence of microbial functions in health and disease, highlighting potential therapeutic targets.

Abstract © the authors / Cell Metabolism (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.cmet.2026.02.012 · PubMed 41831436.

Why it matters for pharma & biotech

  • Relevant to Biology & Life Sciences teams tracking Cell Metabolism for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cell Metabolism study find?

This study provides protein-level evidence of microbial functions in health and disease, highlighting potential therapeutic targets.

What type of study is this?

It is a cohort / observational clinical study, published in Cell Metabolism in 2026. Across metabolic diseases, we observe the consistent depletion of Bacillota species and their proteins involved in carbohydrate, energy, amino acid metabolism, and short-chain fatty acid production.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.cmet.2026.02.012. PubMed ID: 41831436. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Liang S, Sun Y, Miao Z et al.. Large-scale metaproteomics of human gut microbiota reveals microbial functions in metabolic diseases and aging.. Cell Metabolism (2026). DOI: 10.1016/j.cmet.2026.02.012.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/large-scale-metaproteomics-of-human-gut-microbiota-reveals-microbial-fun-602012/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides